Furthermore, TRAIL resistant prostate cancer cells can be sensitised by AKTi co-treatment, which also prevents the TRAIL-induced induction of tumour promoting and pro-metastatic cytokines from the cancer cells, providing an added advantage. The gene discussed is TNFSF10; the disease is prostate cancer.